Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Human Plasma-derived Hyperimmune Product market was valued at US$ 1867 million in 2023 and is anticipated to reach US$ 2839.8 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
This report aims to provide a comprehensive presentation of the global market for Human Plasma-derived Hyperimmune Product, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Plasma-derived Hyperimmune Product.
Report Scope
The Human Plasma-derived Hyperimmune Product market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Plasma-derived Hyperimmune Product market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Plasma-derived Hyperimmune Product manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institution
Private Sector
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Plasma-derived Hyperimmune Product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Plasma-derived Hyperimmune Product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Human Plasma-derived Hyperimmune Product 麻豆原创 Overview
1.1 Product Overview and Scope of Human Plasma-derived Hyperimmune Product
1.2 Human Plasma-derived Hyperimmune Product Segment by Type
1.2.1 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Human Plasma-derived Hyperimmune Product Segment by Application
1.3.1 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Value by Application: (2024-2030)
1.3.2 Government Institution
1.3.3 Private Sector
1.3.4 Others
1.4 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Plasma-derived Hyperimmune Product Revenue 2019-2030
1.4.2 Global Human Plasma-derived Hyperimmune Product Sales 2019-2030
1.4.3 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Plasma-derived Hyperimmune Product 麻豆原创 Competition by Manufacturers
2.1 Global Human Plasma-derived Hyperimmune Product Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Plasma-derived Hyperimmune Product Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Plasma-derived Hyperimmune Product Average Price by Manufacturers (2019-2024)
2.4 Global Human Plasma-derived Hyperimmune Product Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Plasma-derived Hyperimmune Product, Product Type & Application
2.7 Human Plasma-derived Hyperimmune Product 麻豆原创 Competitive Situation and Trends
2.7.1 Human Plasma-derived Hyperimmune Product 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Plasma-derived Hyperimmune Product Players 麻豆原创 Share by Revenue
2.7.3 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Plasma-derived Hyperimmune Product Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Plasma-derived Hyperimmune Product Global Human Plasma-derived Hyperimmune Product Sales by Region: 2019-2030
3.2.1 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2019-2024
3.2.2 Global Human Plasma-derived Hyperimmune Product Sales by Region: 2025-2030
3.3 Global Human Plasma-derived Hyperimmune Product Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2019-2030
3.3.1 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2019-2024
3.3.2 Global Human Plasma-derived Hyperimmune Product Revenue by Region: 2025-2030
3.4 North America Human Plasma-derived Hyperimmune Product 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Plasma-derived Hyperimmune Product Sales by Country (2019-2030)
3.4.3 North America Human Plasma-derived Hyperimmune Product Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Plasma-derived Hyperimmune Product 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2019-2030)
3.5.3 Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Plasma-derived Hyperimmune Product 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Plasma-derived Hyperimmune Product Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Plasma-derived Hyperimmune Product Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Plasma-derived Hyperimmune Product 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Plasma-derived Hyperimmune Product Sales by Country (2019-2030)
3.7.3 Latin America Human Plasma-derived Hyperimmune Product Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Plasma-derived Hyperimmune Product 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Plasma-derived Hyperimmune Product 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Plasma-derived Hyperimmune Product Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2019-2030)
4.1.1 Global Human Plasma-derived Hyperimmune Product Sales by Type (2019-2024)
4.1.2 Global Human Plasma-derived Hyperimmune Product Sales by Type (2025-2030)
4.1.3 Global Human Plasma-derived Hyperimmune Product Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2019-2030)
4.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2019-2024)
4.2.2 Global Human Plasma-derived Hyperimmune Product Revenue by Type (2025-2030)
4.2.3 Global Human Plasma-derived Hyperimmune Product Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Plasma-derived Hyperimmune Product Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2019-2030)
5.1.1 Global Human Plasma-derived Hyperimmune Product Sales by Application (2019-2024)
5.1.2 Global Human Plasma-derived Hyperimmune Product Sales by Application (2025-2030)
5.1.3 Global Human Plasma-derived Hyperimmune Product Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2019-2030)
5.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2019-2024)
5.2.2 Global Human Plasma-derived Hyperimmune Product Revenue by Application (2025-2030)
5.2.3 Global Human Plasma-derived Hyperimmune Product Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Plasma-derived Hyperimmune Product Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Human Plasma-derived Hyperimmune Product Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biotest Human Plasma-derived Hyperimmune Product Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CBPO Human Plasma-derived Hyperimmune Product Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kamada Human Plasma-derived Hyperimmune Product Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CNBG Human Plasma-derived Hyperimmune Product Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Human Plasma-derived Hyperimmune Product Description and Business Overview
6.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Revenue and Gross Margin (2019-2024)
6.12.4 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Plasma-derived Hyperimmune Product Industry Chain Analysis
7.2 Human Plasma-derived Hyperimmune Product Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Plasma-derived Hyperimmune Product Production Mode & Process
7.4 Human Plasma-derived Hyperimmune Product Sales and 麻豆原创ing
7.4.1 Human Plasma-derived Hyperimmune Product Sales Channels
7.4.2 Human Plasma-derived Hyperimmune Product Distributors
7.5 Human Plasma-derived Hyperimmune Product Customers
8 Human Plasma-derived Hyperimmune Product 麻豆原创 Dynamics
8.1 Human Plasma-derived Hyperimmune Product Industry Trends
8.2 Human Plasma-derived Hyperimmune Product 麻豆原创 Drivers
8.3 Human Plasma-derived Hyperimmune Product 麻豆原创 Challenges
8.4 Human Plasma-derived Hyperimmune Product 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
听
听
*If Applicable.